<DOC>
	<DOCNO>NCT00006045</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . It yet know chemotherapy effective without monoclonal antibody therapy acute myelogenous leukemia . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy without monoclonal antibody therapy treat patient refractory relapse acute myelogenous leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Monoclonal Antibody Therapy Treating Patients With Refractory Relapsed Acute Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy , safety , pharmacokinetics , immunogenicity mitoxantrone , etoposide , cytarabine ( MEC ) without monoclonal antibody HuG1-M195 patient refractory relapse acute myelogenous leukemia . OUTLINE : This randomize , multicenter study . Patients stratified age ( 50 vs 50 ) duration previous complete remission ( CR ) ( 0-6 v 7-12 month ) . All patient receive induction chemotherapy comprise cytarabine IV 2 hour , mitoxantrone IV maximum 20 minute , etoposide IV 1-2 hour day 1-6 . On day 5 induction , patient randomize one two treatment arm : Arm I : Patients receive day 6 induction chemotherapy . Patients receive monoclonal antibody HuG1-M195 ( MOAB HuM195 ) IV 4 hour day 6-9 7-10 . Treatment MOAB HuM195 repeat every 2 week 2 course ( course 1 2 ) absence disease progression unacceptable toxicity . During course 1 , MOAB HuM195 begin 30 minute 24 hour postchemotherapy . Patients achieve CR day 70 induction show evidence bone marrow progression ( regimen failure ( RF ) ) take study . Patients without RF assign one two consolidation group base response : Group A ( CR ) : Patients receive consolidation chemotherapy comprise mitoxantrone IV maximum 20 minute day 1 2 , cytarabine IV 2 hour etoposide IV 1-2 hour day 1-4 . Patients New York Heart Association class II heart disease preconsolidation receive mitoxantrone consolidation . Patients receive MOAB HuM195 IV 4 hour day 4-7 5-8 . Treatment MOAB HuM195 repeat every 2 week 2 additional course ( course 3 4 ) . During course 3 , MOAB HuM195 begin 30 minute 24 hour postchemotherapy . Group B ( partial remission ( PR ) , hematologic improvement ( HI ) , stable disease ( SD ) ) : Patients receive MOAB HuM195 group A consolidation chemotherapy . Patients without RF treatment group A B receive maintenance MOAB HuM195 IV 4 hour day 1-4 . Treatment repeat every month 8 additional course ( course 5-12 ) . Arm II : Patients receive day 6 induction chemotherapy . Patients receive MOAB HuM195 entire study . Patients without RF day 70 induction assign one two consolidation group base response : Group C ( CR ) : Patients receive consolidation chemotherapy group A . Group D ( PR , HI , SD ) : Patients receive treatment . Patients may eligible receive MOAB HuM195 PDL Study 195-302 . Patients follow every 3 month 1 year , every 6 month thereafter . PROJECTED ACCRUAL : A maximum 200 patient ( 100 per arm ) accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven acute myelogenous leukemia ( AML ) may primary AML , secondary AML , precede hematologic disorder All FAB subtypes except M3 Must meet one follow three criterion : First relapse within 1 year documentation previous complete remission ( CR ) achieve chemotherapy Refractory prior chemotherapy comprise minimum 1 induction course , include cytarabine minimum 500 mg/m2 ( e.g. , 100 mg/m2/day 5 day ) plus anthracycline No high dose cytarabine ( cumulative dose great 3 g/m2 ) First relapse previous CR subsequent autologous bone marrow transplantation ( BMT ) , follow criterion meet : First BMT At least 100 day less 1 year posttransplantation At least 25 % cellularity bone marrow Previous BMT include full hematopoietic recovery , define follow : Hemoglobin least 10 g/dL ( without transfusion ) Platelet count least 100,000/mm3 ( without transfusion ) Absolute neutrophil count least 1,500/mm3 No transplantation candidate Bone marrow blast ( leukemic cell ) great 10 % No chronic myelogenous leukemia blast crisis No active CNS leukemia PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 50100 % Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin le 2.0 mg/dL ( unless relate Gilbert 's disease due leukemic infiltration ) SGOT SGPT great 4 time upper limit normal ( unless relate AML ) Renal : Creatinine le 2.0 mg/dL ( unless relate AML ) Cardiovascular : Left ventricular function normal No unstable cardiac arrhythmia , unstable angina pectoris , myocardial infarction within past 6 month No New York Heart Association class III IV heart disease No electrocardiogram evidence active ischemia Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month study HIV negative No active malignancy require therapy No active serious infection uncontrolled antimicrobial therapy Medically stable No significant organ dysfunction PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 30 day since prior experimental biologic therapy ( e.g. , interleukin2 ) No concurrent biologic therapy , include bone marrow transplantation Chemotherapy : See Disease Characteristics For first relapse AML recent prior chemotherapy : Prior hydroxyurea give short course ( 48 hour ) allow , need , reduce peripheral leukocyte count Hydroxyurea must discontinue prior study For refractory AML recent prior chemotherapy : Greater 2 week since prior chemotherapy except hydroxyurea give No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No concurrent radiotherapy Surgery : Not specify Other : No concurrent experimental therapy Concurrent therapy preexisting disease allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
</DOC>